| ★ | Kidney involvement in Sjögren’s Disease (SjD) | | 401 | — | |
| 3 | Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 74 |
| 5 | IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 71 |
| 14 | From basics to updates for cutaneous lupus erythematosus (CLE) | | 1.1K | — | 68 |
| 15 | Lanzamiento de la Especialización en Gerencia de Instituciones de la salud | | 720 | Colombia | 68 |
| 10 | Recent advances in the treatment of inflammatory myopathies | | 618 | — | 69 |
| 16 | How to find hidden Antiphospholipid Syndrome (APS) | | 471 | — | 67 |
| 4 | CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 71 |
| 1 | What is the added value of triple therapy in lupus nephritis? | | 438 | — | 77 |
| 17 | Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 67 |
| 8 | Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 69 |
| 11 | Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025? | | 285 | — | 69 |
| 2 | Systemic sclerosis and pregnancy, a 2026 update | | 257 | — | 76 |
| 12 | Thrombocytopenia in systemic lupus erythematosus (SLE) | | 249 | — | 68 |
| 6 | Exercise as a non-pharmacological treatment adjunct to pharmacotherapy in systemic sclerosis. | | 222 | — | 70 |
| 18 | The transition from benign to secondary Raynaud’s phenomenon | | 186 | — | 67 |
| 9 | Unconventional therapies in connective tissue diseases | | 110 | — | 69 |
| 13 | Unmet Needs in Childhood-Onset Sjögren's Disease – Patient and Clinician Perspectives | | 82 | — | 68 |
| 20 | Radiología en Urgencias no Traumáticas I y II | | 58 | — | 66 |
| 7 | Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 69 |
| 19 | Neuromonitorización y Fuentes de Energía, Cirugía de Cáncer Tiroides, Acad. Dr. M. Francisco Herrera | Academia Mexicana de Cirugía A.C. @academiamexdecirugia | 23 | — | 67 |